Prostate cancer detection by targeted prostate biopsy using the 3D Navigo system: a prospective study.
Purpose: The 3D Navigo™ system is a magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion device for prostate targeted biopsies (TB). Our aim was to evaluate the clinically significant prostate cancer (CSC) detection rate of TB using the 3D Navigo™ system. Methods: Patients who u...
| Publicado en: | Abdominal Radiology Vol. 46; no. 9; pp. 4381 - 4388 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Sep2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151776204&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151776204 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2366004X JT14 jtl: Abdominal Radiology issn: 2366004X maglogo: N pubinfo: dt: Sep2021 vid: 46 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 151776204 149822374 10.1007/s00261-021-03078-9 151776204 ppf: 4381 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Prostate cancer detection by targeted prostate biopsy using the 3D Navigo system: a prospective study. aug: au: Magnier, Alexandre Nedelcu, Cosmina Chelly, Samuel Rousselet-Chapeau, Marie-Christine Azzouzi, Abdel Rahmene Lebdai, Souhil affil: Urology Department, University Hospital of Angers, 4 rue Larrey, 49933, Angers Cedex 9, France sug: ab: Purpose: The 3D Navigo™ system is a magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion device for prostate targeted biopsies (TB). Our aim was to evaluate the clinically significant prostate cancer (CSC) detection rate of TB using the 3D Navigo™ system. Methods: Patients who underwent TB with the 3D Navigo™ system in our center between June 2014 and May 2018 were prospectively included, excluding those who have previously received treatment for prostate cancer. A 3-Tesla MRI imaging was performed before biopsies; findings were reported according to the Prostate Imaging Reporting and Data System version 2 (PIRADS). CSC was defined by an ISUP score ≥ 2. Results: 304 patients underwent TB. Median age was 66 years (51–84). Median PSA was 7.75 ng/ml (0.6–70.0). Median prostate volume was 45.0 ml (15.9–221.7). PCa and CSC were found in 70.4% (214/304) and 47.7% (145/304) of the patients, respectively. The proportion of patients diagnosed with CSC among those with PCa was 67.8% (145/214). There was a significant risk of having a CSC in case of PIRADS score ≥ 4 and 5 (OR 5.0, 95% CI [2.7–9.2], P < 0.001; OR 3.2, 95% CI [1.8–5.5], P < 0.001). PIRADS score was an independent risk factor of having a CSC (OR 4.19, 95% CI [2.49–7.05], P < 0.001). There was no significant difference between pathological outcomes of TB and RP in paired analysis (P = 0.892). There was a correlation between TB and RP specimens for PCa detection (r = 0.60, P < 0.001). Conclusion: Detecting CSC with MRI-TRUS fusion targeted biopsies using the 3D Navigo™ system is feasible and safe. We found a positive correlation between TB and RP for ISUP scores. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|